[225Ac]-PTR-58

N/A

Report date: 2025/11/20 16:04:44
NME

Base Information

Drug Name[225Ac]-PTR-58
Drug Alias Name[225Ac]-PTR-58225Ac-PTR58
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[5] 
Mechanisms of ActionSomatostatin receptor 3 modulators
TargetsSomatostatin receptor 3
Therapy Area/IndicationsCarcinoma, HepatocellularMelanomaNeuroendocrine Tumors +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStarget Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesStarget Pharma Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, HepatocellularMelanomaNeuroendocrine Tumors +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A